SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

ARV-102

ARVN·Arvinas Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Years away. ARV-102 is in Phase 1 for Parkinson's disease. The PSP Phase 1b trial is expected to begin in 2027 in the EU/UK. Even if successful, Phase 2 and Phase 3 trials would be needed before any regulatory filing, likely several years away.
Why 4/10
ARV-102 has no PDUFA or pivotal readout in the next ~12 months. The next catalyst is the submission of a clinical trial application (CTA) for the EU Phase 1b PSP trial (targeted Q4 2026) and UK (Q1 2027), followed by trial initiation in 2027. These are regulatory/operational milestones, not binary efficacy readouts. ARV-102 is one of several pipeline programs at Arvinas, and the stock's near-term focus is on ARV-393 data at ASH (December 2026). Impact score 4 reflects early-stage status, a US clinical hold overhang, and no near-term binary catalyst.
Actionable Insight NEUTRAL

Watch for the EU CTA submission for the PSP Phase 1b trial (targeted Q4 2026) and any resolution of the US clinical hold. Positive regulatory progress could lift the stock, while further delays or negative safety signals from the ongoing Parkinson's Phase 1 would pressure shares. The stock already trades near its 52-week low ($6.74) with a $558.9M cash runway into H2 2028.

Price Chart

Loading chart...

Executive Summary

ARV-102 is Arvinas's oral PROTAC degrader targeting the LRRK2 protein for neurodegenerative diseases, primarily Parkinson's disease and progressive supranuclear palsy (PSP). Phase 1 data showed the drug is well-tolerated, crosses the blood-brain barrier, and achieved >50% LRRK2 degradation in cerebrospinal fluid after 28 days. However, the planned US Phase 1b PSP trial is on FDA clinical hold, and the company has shifted to a European strategy, targeting CTA submission in the EU in Q4 2026 and UK in Q1 2027, with trial initiation in 2027. The stock trades near its 52-week low ($7.09) with a $558.9M cash runway into H2 2028. ARV-102 is one of several pipeline assets; the nearer-term catalyst for Arvinas is ARV-393 (BCL6 degrader) data at ASH in December 2026.

How It Works

ARV-102 is an oral PROTAC (PROteolysis TArgeting Chimera) that works like a molecular garbage truck. It is designed to enter the brain, find the LRRK2 protein (implicated in Parkinson's and related diseases), tag it for destruction, and let the cell's natural disposal system break it down. Unlike traditional drugs that only block a protein's activity, PROTACs eliminate the protein entirely.

Trial Status

Phase 1 SAD/MAD in healthy volunteers completed. Phase 1 multiple-dose trial in Parkinson's disease patients (ARV-102-103) is ongoing, with positive biomarker and oculomotor data presented at MDS 2026 (October 2026). The planned US Phase 1b PSP trial is on FDA clinical hold. Company plans to submit a CTA for an EU Phase 1b PSP trial in Q4 2026 and UK in Q1 2027, with trial initiation in 2027.

The Two-Sided Case

▲ Bull Case5
Phase 1 data showed >50% LRRK2 degradation in CSF of Parkinson's patients after 28 days, with good tolerability and brain penetration, validating the PROTAC approach in the CNS.
Oculomotor and biomarker data presented at MDS 2026 (October 2026) showed improvements in eye-movement measures correlated with biomarker changes, suggesting target engagement and potential clinical benefit.
Arvinas has $558.9M in cash with runway into H2 2028, sufficient to fund multiple pipeline programs including ARV-102 through several catalysts.
Analyst consensus is positive: 13 Buy/Strong Buy ratings vs 1 Sell, with a mean price target of $14.54 (93% upside from $7.52).
The LRRK2 space has cleared out competitors (Biogen/Denali exited), potentially reducing future competition if ARV-102 succeeds.
▼ Bear Case5
The planned US Phase 1b PSP trial is on FDA clinical hold, with no disclosed resolution timeline, creating regulatory uncertainty.
The LRRK2 target class suffered a major setback: Biogen/Denali's BIIB122 failed a Phase 2b study and was discontinued for idiopathic Parkinson's, raising questions about the mechanism.
ARV-102 is still in Phase 1 with no pivotal or registrational trial data expected for years; the next catalyst is a regulatory filing (CTA), not a binary efficacy readout.
The stock trades near its 52-week low ($6.74) and has fallen ~51% from its 52-week high ($14.51), reflecting pipeline skepticism.
ARV-102 is one of several early-stage programs; the company's lead near-term catalyst is ARV-393 (BCL6) data at ASH in December 2026, not ARV-102.

Upcoming Catalysts

  • EU CTA submission for PSP Phase 1b trial (targeted Q4 2026)
  • UK CTA submission for PSP Phase 1b trial (targeted Q1 2027)
  • Initiation of Phase 1b PSP trial in EU/UK (targeted 2027)
  • Potential resolution of US clinical hold (no timeline disclosed)
  • Additional Phase 1 biomarker data readouts from ongoing Parkinson's trial

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Arvinas Inc. PRESS-RELEASE ARVN ·Originating report

Sources · 9

Hover a chip for the title
1 ir.arvinas.com2 markets.businessinsider.com3 markets.businessinsider.com4 fool.com5 arvinas.com6 seekingalpha.com7 fiercebiotech.com8 ir.arvinas.com9 marketbeat.com